» Articles » PMID: 28883399

Antibiotic Treatment for Tuberculosis Induces a Profound Dysbiosis of the Microbiome That Persists Long After Therapy is Completed

Overview
Journal Sci Rep
Specialty Science
Date 2017 Sep 9
PMID 28883399
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Mycobacterium tuberculosis, the cause of Tuberculosis (TB), infects one third of the world's population and causes substantial mortality worldwide. In its shortest format, treatment of TB requires six months of multidrug therapy with a mixture of broad spectrum and mycobacterial specific antibiotics, and treatment of multidrug resistant TB is longer. The widespread use of this regimen makes this one of the largest exposures of humans to antimicrobials, yet the effects of TB treatment on intestinal microbiome composition and long-term stability are unknown. We compared the microbiome composition, assessed by both 16S rDNA and metagenomic DNA sequencing, of TB cases during antimycobacterial treatment and following cure by 6 months of antibiotics. TB treatment does not perturb overall diversity, but nonetheless dramatically depletes multiple immunologically significant commensal bacteria. The microbiomic perturbation of TB therapy can persist for at least 1.2 years, indicating that the effects of TB treatment are long lasting. These results demonstrate that TB treatment has dramatic effects on the intestinal microbiome and highlight unexpected durable consequences of treatment for the world's most common infection on human ecology.

Citing Articles

Bifidobacterium adolescentis is resistant to pyrazinamide, isoniazid, and streptomycin.

Nellikka A, Cheruvari A, Vasu P, Mutturi S, Rajagopal K Sci Rep. 2024; 14(1):29562.

PMID: 39609447 PMC: 11605034. DOI: 10.1038/s41598-024-78095-x.


People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.

Juste M, Joseph Y, Lespinasse D, Apollon A, Jamshidi P, Lee M Pathog Immun. 2024; 9(2):172-193.

PMID: 39345793 PMC: 11432494. DOI: 10.20411/pai.v9i2.722.


Subtracting the background by reducing cell-free DNA's confounding effects on Mycobacterium tuberculosis quantitation and the sputum microbiome.

Naidoo C, Venter R, Codony F, Agusti G, Kitchin N, Naidoo S Sci Rep. 2024; 14(1):22350.

PMID: 39333362 PMC: 11436789. DOI: 10.1038/s41598-024-73497-3.


The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections.

Sey E, Warris A Oxf Open Immunol. 2024; 5(1):iqae008.

PMID: 39193472 PMC: 11316619. DOI: 10.1093/oxfimm/iqae008.


Microbiota alterations in patients treated for susceptible or drug-resistant TB.

Hauptmann M, Kalsdorf B, Akoh-Arrey J, Lange C, Schaible U IJTLD Open. 2024; 1(8):355-361.

PMID: 39131591 PMC: 11308407. DOI: 10.5588/ijtldopen.24.0325.


References
1.
Schirmer M, Smeekens S, Vlamakis H, Jaeger M, Oosting M, Franzosa E . Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell. 2016; 167(7):1897. DOI: 10.1016/j.cell.2016.11.046. View

2.
Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett W . Metagenomic biomarker discovery and explanation. Genome Biol. 2011; 12(6):R60. PMC: 3218848. DOI: 10.1186/gb-2011-12-6-r60. View

3.
Furusawa Y, Obata Y, Fukuda S, Endo T, Nakato G, Takahashi D . Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013; 504(7480):446-50. DOI: 10.1038/nature12721. View

4.
Glynn J, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P . High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis. 2010; 201(5):704-11. DOI: 10.1086/650529. View

5.
Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View